Advertisement
Advertisement
U.S. markets open in 6 hours 34 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Cognition Therapeutics, Inc. (CGTX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.92+0.03 (+0.34%)
At close: 1:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.89
Open8.62
Bid0.00 x 900
Ask0.00 x 1100
Day's Range8.26 - 9.35
52 Week Range8.26 - 13.80
Volume18,072
Avg. Volume165,528
Market Cap196.565M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-20.30
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CGTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cognition Therapeutics, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    10 days agoMorningstar
View more
  • GlobeNewswire

    Cognition Therapeutics Reports Third Quarter Financial Results and Company Highlights

    Capital from upsized IPO plus substantial NIA grants supports clinical progress of novel small-molecule σ-2 modulators into new indicationsPURCHASE, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today re

  • GlobeNewswire

    Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

    PURCHASE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the closing of an additional 565,217 shares of its common stock following the exercise in full of the underwriters’ over-allotment

  • GlobeNewswire

    Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

    PURCHASE, N.Y., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the addition of Ellen B. Richstone to the company’s board of directors, where she will serve as the chair of the audit committee. M

Advertisement
Advertisement